Chisholm JC, Schoot RA, Cameron AL, Casanova M, Minard-Colin V, Coppadoro B, Garrido B, Rogers B, Orbach D, Glosli H, Ben-Arush M, Ferman S, Scarzello G, van Rijn RR, Hladun R, Corradini N, Ferrari A, Jenney M, Bisogno G, Merks JHM. EJC 2023. https://doi.org/10.1016/j.ejcped.2023.100018
Among patients with metastatic rhabdomyosarcoma, outcomes are better in patients for whom lung is the only metastatic site. Oberlin has also identified 4 risk factors that are associated with adverse outcomes in metastatic rhabdomyosarcoma. This study reported on the clinical features, management and outcomes by Oberlin risk factors and use of lung radiotherapy in patients with lung-only metastatic rhabdomyosarcoma treated within the EpSSG MTS 2008 study.
Fifty nine patients with lung-only metastatic disease were identified among 270 registered in the MTS 2008 study. Their 3-yr Event Free Survival (EFS) was 40% (95%CI 27-53%) and 3-yr Overall Survival (OS) was 60% (95%CI 46-71%), better than published outcomes for the whole MTS 2008 group (3-year EFS 35%, OS 48%) . OS was significantly improved compared to patients with lung + other metastatic sites or other metastatic sites but outcomes did not differ between these groups when adjusted for known Oberlin risk factors. Radiotherapy to the lungs appeared to improve 3-year EFS but not OS (EFS: RT 56%, 95%CI 35-73% versus no RT 33%, 95%CI 16-52%, p= 0.0435. OS: 73%, 95%CI 51-86% versus 58%, 95%CI 36-75%; p=0.2048.
Overall it was concluded that better OS in lung-only MTS RMS is associated with fewer Oberlin risk factors and radiotherapy to the lung is recommended for patients with lung-only metastatic rhabdomyosarcoma.
Fifty nine patients with lung-only metastatic disease were identified among 270 registered in the MTS 2008 study. Their 3-yr Event Free Survival (EFS) was 40% (95%CI 27-53%) and 3-yr Overall Survival (OS) was 60% (95%CI 46-71%), better than published outcomes for the whole MTS 2008 group (3-year EFS 35%, OS 48%) . OS was significantly improved compared to patients with lung + other metastatic sites or other metastatic sites but outcomes did not differ between these groups when adjusted for known Oberlin risk factors. Radiotherapy to the lungs appeared to improve 3-year EFS but not OS (EFS: RT 56%, 95%CI 35-73% versus no RT 33%, 95%CI 16-52%, p= 0.0435. OS: 73%, 95%CI 51-86% versus 58%, 95%CI 36-75%; p=0.2048.
Overall it was concluded that better OS in lung-only MTS RMS is associated with fewer Oberlin risk factors and radiotherapy to the lung is recommended for patients with lung-only metastatic rhabdomyosarcoma.
